Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

BACKGROUND. The standard treatment for chronic phase chronic myeloid leukemia (CML) is lifelong oral tyrosine kinase inhibitor (TKI) therapy. Multiple clinical trials have demonstrated that some patients with a sustained deep molecular response to TKI therapy can safely stop therapy and remain in a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Flynn, Kathryn E., Myers, Judith M., D'Souza, Anita, Schiffer, Charles A., Thompson, James E., Atallah, Ehab
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Inc. 2019
Предметы:
Hematologic Malignancies
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738285/
https://ncbi.nlm.nih.gov/pubmed/30944185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0831
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы